Medical News Today -- Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announcedthat a publication entitled “TRO40303 (3,5-seco-4-nor-cholestan-5-one oxime-3-ol), a new cardioprotective compound, inhibits mitochondrial permeability transition” was published in the June issue of the Journal of Pharmacology And Experimental Therapeutics and on-line 9 March 2010.The studies reported in the paper by Schaller et al.,[1] demonstrate the potential for this compound to protect heart tissue from ischemia-reperfusion injury induced when treating myocardial infarction (MI, commonly referred to as a heart attack).
